Gastric cancer is a major cause of cancer-related morbidity and mortality worldwide. Advances in targeted medical treatment were scarce in the past and challenged by the marked spatial and temporal biological heterogeneity of gastric cancer. Recent molecular profiling studies have increased our understanding of genetic and epigenetic drivers, leading to better patient selection for drug development. Beyond that, immune-related biomarkers were identified, paving the way for future effective immunotherapy. We systematically reviewed articles from PubMed of the past 10 years, and abstracts from annual meetings of ESMO, ASCO and AACR to summarise the current knowledge about targeted and immunotherapy and outline pathways to future personalised therapy of gastric cancer.

胃癌是全世界与癌症相关的发病率和死亡率的主要原因。过去，靶向治疗的进展很少，并且受到胃癌明显的时空生物学异质性的挑战。最近的分子谱分析研究增加了我们对遗传和表观遗传驱动因素的了解，从而为药物开发选择了更好的患者。除此之外，还可以识别与免疫相关的生物标志物，为将来的有效免疫治疗铺平了道路。我们系统地回顾了过去10年中PubMed的文章，以及ESMO，ASCO和AACR年度会议的摘要，以总结关于靶向和免疫疗法的当前知识，并概述了未来胃癌个性化治疗的途径。